Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Therapies that modulate inflammation and fibrosis have the potential to reduce the morbidity and mortality associated with chronic kidney disease (CKD). A promising avenue may be manipulating thymosin-β4, a naturally occurring peptide, which is the major G-actin sequestering protein in mammalian cells and a regulator of inflammation and fibrosis. Thymosin-β4 is already being tested in clinical trials for heart disease and wound healing. This editorial outlines the evidence that thymosin-β4 may also have therapeutic benefit in CKD.

Original publication




Journal article


Expert Opin Biol Ther

Publication Date



15 Suppl 1


S187 - S190


Ac-SDKP, fibrosis, inflammation, kidney disease, thymosin-β4, Adult, Animals, Fibrosis, Humans, Inflammation, Kidney, Mice, Rats, Renal Insufficiency, Chronic, Thymosin, Wound Healing